World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0014771853
Reproduction Date:

Title: Cav1.1  
Author: World Heritage Encyclopedia
Language: English
Subject: Thyrotoxic periodic paralysis, Channelopathy, Erythrokeratodermia variabilis, Bart–Pumphrey syndrome, Clouston's hidrotic ectodermal dysplasia
Collection: Ion Channels
Publisher: World Heritage Encyclopedia


Calcium channel, voltage-dependent, L type, alpha 1S subunit
Available structures
PDB Ortholog search: PDBe, RCSB
Symbols  ; CACNL1A3; CCHL1A3; Cav1.1; HOKPP; HOKPP1; MHS5; TTPP1; hypoPP
External IDs IUPHAR: ChEMBL: GeneCards:
RNA expression pattern
Species Human Mouse
RefSeq (mRNA)
RefSeq (protein)
Location (UCSC)
PubMed search

Cav1.1 also known as the calcium channel, voltage-dependent, L type, alpha 1S subunit, (CACNA1S), is a protein which in humans is encoded by the CACNA1S gene.[1] It is also known as CACNL1A3 and the dihydropyridine receptor (DHPR, so named due to the blocking action DHP has on it).


  • Function 1
  • Clinical significance 2
  • Blockers 3
  • See also 4
  • References 5
  • Further reading 6
  • External links 7


This gene encodes one of the five subunits of the slowly inactivating L-type voltage-dependent calcium channel in skeletal muscle cells. Mutations in this gene have been associated with hypokalemic periodic paralysis, thyrotoxic periodic paralysis and malignant hyperthermia susceptibility.[1]

Cav1.1 is a voltage-dependent calcium channel found in the transverse tubule of muscles. In skeletal muscle it associates with the ryanodine receptor RyR1 of the sarcoplasmic reticulum via a mechanical linkage. It senses the voltage change caused by the end-plate potential from nervous stimulation and propagated by sodium channels as action potentials to the T-tubules. It was previously thought that when the muscle depolarises, the calcium channel opens, allowing calcium in and activating RyR1, which mediates much greater calcium release from the sarcoplasmic reticulum. This is the first part of the process of excitation-contraction coupling, which ultimately causes the muscle to contract. Recent findings suggest that in skeletal muscle (but not heart muscle), calcium entry through Cav1.1 is not required; Cav1.1 undergoes a conformational change which allosterically activates RyR1.[2]

Clinical significance

In hypokalemic periodic paralysis (HOKPP), the voltage sensors in domains 2 and 4 of Cav1.1 are mutated (loss-of-function), reducing the availability of the channel to sense depolarisation, and therefore it cannot activate the ryanodine receptor as efficiently. As a result, the muscle cannot contract very well and the patient is paralysed. The condition is hypokalemic because a low extracellular potassium ion concentration will cause the muscle to repolarise to the resting potential more quickly, so any calcium conductance that does occur cannot be sustained. It becomes more difficult to reach the threshold at which the muscle can contract, and even if this is reached then the muscle is more prone to relaxing. Because of this, the severity would be reduced if potassium ion concentrations are maintained. In contrast, hyperkalemic periodic paralysis refers to gain-of-function mutations in sodium channels that maintain muscle depolarisation and therefore are aggravated by high potassium ion concentrations.[3]


Cav1.1 is blocked by dihydropyridine.

See also


  1. ^ a b "Entrez Gene: CACNA1S calcium channel, voltage-dependent, L type, alpha 1S subunit". 
  2. ^ Proenza C, O'Brien J, Nakai J, Mukherjee S, Allen PD, Beam KG (February 2002). "Identification of a region of RyR1 that participates in allosteric coupling with the alpha(1S) (Ca(V)1.1) II-III loop". J. Biol. Chem. 277 (8): 6530–5.  
  3. ^ Jurkat-Rott K, Lehmann-Horn F (August 2005). "Muscle channelopathies and critical points in functional and genetic studies". J. Clin. Invest. 115 (8): 2000–9.  

Further reading

  • Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J (2006). "International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels". Pharmacol. Rev. 57 (4): 411–25.  
  • Rotman EI, De Jongh KS, Florio V, et al. (1992). "Specific phosphorylation of a COOH-terminal site on the full-length form of the alpha 1 subunit of the skeletal muscle calcium channel by cAMP-dependent protein kinase". J. Biol. Chem. 267 (23): 16100–5.  
  • Röhrkasten A, Meyer HE, Nastainczyk W, et al. (1988). "cAMP-dependent protein kinase rapidly phosphorylates serine- 687 of the skeletal muscle receptor for calcium channel blockers". J. Biol. Chem. 263 (30): 15325–9.  
  • Tanabe T, Takeshima H, Mikami A, et al. (1987). "Primary structure of the receptor for calcium channel blockers from skeletal muscle". Nature 328 (6128): 313–8.  
  • Hogan K, Powers PA, Gregg RG (1995). "Cloning of the human skeletal muscle alpha 1 subunit of the dihydropyridine-sensitive L-type calcium channel (CACNL1A3)". Genomics 24 (3): 608–9.  
  • Elbaz A, Vale-Santos J, Jurkat-Rott K, et al. (1995). "Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families". Am. J. Hum. Genet. 56 (2): 374–80.  
  • Boerman RH, Ophoff RA, Links TP, et al. (1995). "Mutation in DHP receptor alpha 1 subunit (CACLN1A3) gene in a Dutch family with hypokalaemic periodic paralysis". J. Med. Genet. 32 (1): 44–7.  
  • Gregg RG, Couch F, Hogan K, Powers PA (1993). "Assignment of the human gene for the alpha 1 subunit of the skeletal muscle DHP-sensitive Ca2+ channel (CACNL1A3) to chromosome 1q31-q32". Genomics 15 (1): 107–12.  
  • Jurkat-Rott K, Lehmann-Horn F, Elbaz A, et al. (1995). "A calcium channel mutation causing hypokalemic periodic paralysis". Hum. Mol. Genet. 3 (8): 1415–9.  
  • Ptácek LJ, Tawil R, Griggs RC, et al. (1994). "Dihydropyridine receptor mutations cause hypokalemic periodic paralysis". Cell 77 (6): 863–8.  
  • Drouet B, Garcia L, Simon-Chazottes D, et al. (1994). "The gene coding for the alpha 1 subunit of the skeletal dihydropyridine receptor (Cchl1a3 = mdg) maps to mouse chromosome 1 and human 1q32". Mamm. Genome 4 (9): 499–503.  
  • Iles DE, Segers B, Olde Weghuis D, et al. (1994). "Refined localization of the alpha 1-subunit of the skeletal muscle L-type voltage-dependent calcium channel (CACNL1A3) to human chromosome 1q32 by in situ hybridization". Genomics 19 (3): 561–3.  
  • O'Brien RO, Taske NL, Hansbro PM, et al. (1996). "Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia". J. Med. Genet. 32 (11): 913–4.  
  • Hogan K, Gregg RG, Powers PA (1997). "The structure of the gene encoding the human skeletal muscle alpha 1 subunit of the dihydropyridine-sensitive L-type calcium channel (CACNL1A3)". Genomics 31 (3): 392–4.  
  • Robinson RL, Monnier N, Wolz W, et al. (1997). "A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees". Hum. Mol. Genet. 6 (6): 953–61.  
  • Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997). "Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle". Am. J. Hum. Genet. 60 (6): 1316–25.  
  • Meyers MB, Puri TS, Chien AJ, et al. (1998). "Sorcin associates with the pore-forming subunit of voltage-dependent L-type Ca2+ channels". J. Biol. Chem. 273 (30): 18930–5.  
  • Morrill JA, Brown RH, Cannon SC (1999). "Gating of the L-type Ca channel in human skeletal myotubes: an activation defect caused by the hypokalemic periodic paralysis mutation R528H". J. Neurosci. 18 (24): 10320–34.  
  • Protasi F, Paolini C, Nakai J, et al. (2003). "Multiple regions of RyR1 mediate functional and structural interactions with alpha(1S)-dihydropyridine receptors in skeletal muscle". Biophys. J. 83 (6): 3230–44.  
  • Carsana A, Fortunato G, De Sarno C, et al. (2003). "Identification of new polymorphisms in the CACNA1S gene". Clin. Chem. Lab. Med. 41 (1): 20–2.  

External links

  • GeneReviews/NCBI/NIH/UW entry on Malignant Hyperthermia Susceptibility
  • CACNA1S protein, human at the US National Library of Medicine Medical Subject Headings (MeSH)

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.